The EU contract with the American pharmaceutical company Novavax for the supply of up to 200 million doses coronavirus vaccines for the period 2021-2023 was signed on Monday (16/8) by the commissioner in charge of health issues Stella Kyriakidou.
This preparation should be tested and approved by the European Medicines Agency as safe and effective.
“By signing with Novavax the contract for the supply of up to 200 million additional doses of vaccine against covid-19 in 2021 and 2023, we are adding a promising vaccine technology to our portfolio and ensure their supply for the EU and the planet as we prepare for the coming monthsPointed out the Stella Kyriakidou as broadcast by the Athenian News Agency.
The current contract is added to the already wide portfolio of vaccines to be produced in Europe, which includes the contracts with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNtech-Pfizer, CureVac, Moderna, as well as the integrated exploratory talks with Valneva.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
